Keyword

MEK162

Description: An orally administered small-molecule inhibitor of MEK1 and MEK2 investigated as a treatment for cancers with MAPK pathway alterations.
Wikidata ID: wiki/Q19903515
OpenAlex ID: keywords/mek162
2013 · Akintunde Akinleye, Muhammad Furqan, et al. · Journal of Hematology & Oncology · 323
2017 · Johanna C Bendell, Milind Javle, et al. · British Journal of Cancer · 139
2014 · U. Urner-Bloch, M. Urner, et al. · Annals of Oncology · 136
2014 · Caela R. Miller, Kate E. Oliver, et al. · Gynecologic Oncology · 109
2014 · Jaykumar Thumar, David Shahbazian, et al. · Molecular Cancer · 84
2021 · Mehran Pashirzad, Reihaneh Khorasanian, et al. · Current Cancer Drug Targets · 74
2014 · Heidi VN Küsters-Vandevelde, Annelieke ECAB Willemsen, et al. · Acta Neuropathologica Communications · 70
2016 · Jinfeng Cao, Renier C. Heijkants, et al. · Oncotarget · 69
2014 · Kira Gritsman, Haluk Yuzugullu, et al. · Journal of Clinical Investigation · 62
2014 · Vito W. Rebecca, Gretchen M. Alicea, et al. · Pigment Cell & Melanoma Research · 60
2014 · Dejan Juric, Jean-Charles Soria, et al. · Journal of Clinical Oncology · 57
2012 · Richard S. Finn, Milind M. Javle, et al. · Journal of Clinical Oncology · 50
2016 · Erin E. Talbert, Jennifer Yang, et al. · Molecular Cancer Therapeutics · 37
Works count: 143
Citation count: 3,516
Year
Topic
Type